

K 942277

SEP 6 1994

**SUMMARY OF SAFETY AND EFFECTIVENESS****Vitamin B<sub>12</sub> Method for TECHNICON IMMUNO-1® System**

Listed below is a comparison of the performance between the IMMUNO-1 B<sub>12</sub> method and a similar device that was granted clearance of substantial equivalence (BioRad Quantaphase radioassay method). The information used in the Summary of Safety and Effectiveness was extracted from the IMMUNO-1 B<sub>12</sub> method sheets and from data on file at Miles, Inc.

**INTENDED USE**

This *in vitro* diagnostic procedure is intended to quantitatively measure Vitamin B<sub>12</sub> in human serum on the Technicon IMMUNO-1® system. Measurements of Vitamin B<sub>12</sub> are used in the diagnosis and treatment of anemia.

<b>METHOD</b>	<b>IMMUNO-1 B<sub>12</sub></b>	<b>BioRad Quantaphase (predicate Device)</b>
<b>Part No.</b>	T01-3462-01	192 5001
<b>Minimum Detectable Conc.</b>	25 pg/mL	20 pg/mL
<b>Precision (Between-Run)</b>	170 pg/mL 10.1% 250 pg/mL 7.4% 1000 pg/mL 6.0%	157 pg/mL 8.3% 477 pg/mL 2.7% 1239 pg/mL 2.7%
<b>Linearity</b>	0 - 2000 pg/mL	0 - 2000 pg/ml
<b>Correlation</b>	$y = 0.95 x + 19$  where $y = \text{IMMUNO-1 B}_{12} \text{ assay}; x = \text{BioRad Quantaphase method}$ $n = 46$ $r = 0.99$ $S_{yx} = 40 \text{ pg/mL}$	
<b>SPECIFICITY*</b>		
<b>(Cross-Reactivity of cobinamide)</b>	< 26 pg/mL	< 66 pg/mL

\* The cross-reactivity of cobinamide was determined by assaying several samples before and after spiking with 10,000 pg/mL cobinamide. The data shown are the maximum net change in assayed B<sub>12</sub> level.